Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$680M |
| 2 |
Microsoft
MSFT
|
+$506M |
| 3 |
UnitedHealth
UNH
|
+$393M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$381M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$348M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.24B |
| 2 |
Tesla
TSLA
|
+$450M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$444M |
| 4 |
TSMC
TSM
|
+$432M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.79% |
| 2 | Consumer Discretionary | 0.82% |
| 3 | Financials | 0.79% |
| 4 | Healthcare | 0.66% |
| 5 | Industrials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11976
CALL
Karyopharm Therapeutics
KPTI
$44.5M
| $71.5K | ﹤0.01% |
16,600
-47,200
| -74% | -$232K |
|
11977
PUT
Lifestance Health
LFST
$4.64B
| $71.3K | ﹤0.01% |
13,800
-19,900
| -59% | -$119K |
|
|
NOTE
11978
CALL
DELISTED
FiscalNote
NOTE
| $71.3K | ﹤0.01% |
11,008
-1,684
| -13% | -$12.6K |
|
|
HITI
11979
High Tide
HITI
$221M
| $71.2K | ﹤0.01% |
30,959
-364,661
| -92% | -$818K |
|
11980
CALL
Citizens
CIA
$199M
| $71.2K | ﹤0.01% |
20,400
-20,000
| -50% | -$78.1K |
|
11981
CALL
WidePoint Corp
WYY
$94.5M
| $71.1K | ﹤0.01% |
20,800
+2,400
| +13% | +$8.6K |
|
|
BRY
11982
PUT
DELISTED
Berry Corp
BRY
| $70.9K | ﹤0.01% |
+25,600
| New | +$68.4K |
|
11983
KNOT Offshore Partners
KNOP
$368M
| $70.7K | ﹤0.01% |
+11,296
| New | +$73.7K |
|
11984
CALL
Rackspace Technology
RXT
$867M
| $70.7K | ﹤0.01% |
55,200
-129,400
| -70% | -$169K |
|
|
CAN
11985
PUT
Canaan Creative
CAN
$297M
| $70.6K | ﹤0.01% |
113,900
-205,100
| -64% | -$144K |
|
11986
PUT
Voyager Therapeutics
VYGR
$213M
| $70.6K | ﹤0.01% |
+22,700
| New | +$73.2K |
|
11987
UNIFI
UFI
$140M
| $70K | ﹤0.01% |
13,417
-95,714
| -88% | -$471K |
|
11988
CALL
eHealth
EHTH
$38.1M
| $70K | ﹤0.01% |
16,100
-30,400
| -65% | -$153K |
|
11989
ICL Group
ICL
$7.33B
| $70K | ﹤0.01% |
10,175
-7,761
| -43% | -$50.7K |
|
11990
Data I/O
DAIO
$30.3M
| $69.7K | ﹤0.01% |
+22,708
| New | +$57.2K |
|
11991
Natural Health Trends
NHTC
$14.7M
| $69.6K | ﹤0.01% |
+15,669
| New | +$75.2K |
|
11992
Genprex
GNPX
$3.25M
| $69.4K | ﹤0.01% |
+277
| New | +$84.6K |
|
|
HIX
11993
Western Asset High Income Fund II
HIX
$352M
| $69.2K | ﹤0.01% |
16,124
+4,617
| +40% | +$19.1K |
|
|
VTYX
11994
PUT
DELISTED
Ventyx Biosciences
VTYX
| $69.1K | ﹤0.01% |
32,300
+13,100
| +68% | +$21.2K |
|
|
SANG
11995
Sangoma Technologies
SANG
$129M
| $68.6K | ﹤0.01% |
11,337
-1,288
| -10% | -$6.99K |
|
11996
PUT
Larimar Therapeutics
LRMR
$433M
| $68.5K | ﹤0.01% |
23,700
-29,100
| -55% | -$67.4K |
|
11997
System1
SST
$16.1M
| $68.4K | ﹤0.01% |
12,374
+8,342
| +207% | +$37K |
|
11998
Dyadic International
DYAI
$26.4M
| $68.2K | ﹤0.01% |
68,929
-14,692
| -18% | -$16.1K |
|
11999
CALL
Gain Therapeutics
GANX
$79M
| $68.2K | ﹤0.01% |
+37,900
| New | +$70.1K |
|
|
KNDI
12000
CALL
Kandi Technologies Group
KNDI
$66.1M
| $68K | ﹤0.01% |
61,300
-31,900
| -34% | -$37.2K |
|
Similar funds
Jeff Yass's Q2 2025 Portfolio in Review
As of Q2 2025, Jeff Yass held 14,080 positions worth $720B, up 23% from $586B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jeff Yass deployed $32.3B of net new capital in Q2 2025, opening 1,720 new positions and adding to 5,716 existing holdings. Its largest new stake was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
By sector, the portfolio is most concentrated in Technology at 1.8% of assets, up from 1.6% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $5.24B trimmed.
- Jeff Yass's largest Q2 2025 buy was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
- Jeff Yass added most to Apple in Q2 2025, an estimated $680M increase.
- Jeff Yass's biggest Q2 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.24B.
- Jeff Yass fully exited Vanguard Intermediate-Term Bond ETF in Q2 2025, selling an estimated $61.8M.
- Jeff Yass's ten largest holdings make up 26% of its $720B portfolio in Q2 2025.
- Jeff Yass opened 1,720 new positions and closed 1,538 in Q2 2025.
- Jeff Yass's portfolio value rose 23% quarter-over-quarter to $720B.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.